Emcure’s Bet: Skip the US, Own Europe and Canada Instead
Senior Director, Windmill Capital | The content in this article is purely the author’s personal opinion and is for informational and educational purposes only. It should not be construed as professional financial advice and nor to be construed as an offer to buy /sell or the solicitation of an offer to buy / sell any security or financial products.
The views and opinions stated in the content belong to the author. Windmill Capital Private Limited does not uphold nor promote any of the views / opinions. | Windmill Capital Private Limited is a SEBI registered research analyst (Regn. No. INH200007645)
Emcure’s Bet: Skip the US, Own Europe and Canada Instead
Most Indian pharma majors chase the US market. Emcure deliberately avoided it. Here's what it built instead.
Windmill Capital Investor Letter – July 2026 Edition
July was the month earnings did the heavy lifting. Strong Q1 FY27 results and a Fed on hold pushed Indian equities higher even as crude oil climbed and geopolitical tension stayed elevated all month.
₹1 Lakh, One Crash, Three Very Different Outcomes
Three investors put money into the exact same strategy right before a market crash. One panicked and sold. One held on. One kept a monthly SIP going through it all. Same crash, same strategy; wildly different outcomes. Here's what actually separated them.
Strategic Analysis: The Persistent-Nagarro $2.9 Billion AI Consolidation
Persistent Systems just agreed to buy Germany's Nagarro SE for $1.3 billion and paid a jaw-dropping 140% premium to do it! We explain this deal in plain English.
HCLTech Is Down 36% This Year, Here’s What It’s Betting On Next
HCLTech moves into chip manufacturing with Foxconn, a lead investment in India's sovereign AI project Sarvam, and a retraining push across 135,000 employees.
What Happens After a Pharma Company Gets an FDA Warning Letter?
Clean FDA inspections at three facilities, two ADHD drug approvals, and a first profitable quarter for its new peptide business, Granules India's FY26 shows what a recovery from a warning letter actually looks like.